

More detail on each of these medications can be found in our **medications factsheets** that summarise the key information, including potential side effects, to provide you with background information that you can then discuss with your healthcare providers.

	Disease Modifying Therapies (DMTs)														Symptomatic Therapies			
	oral tablet						injection						infusion					
Brand name	Aubagio® note 1	Gilenya®	MAVENCLAD®	Mayzent®	Tecfidera®	Zeposia®	Avonex®	Betaferon®	Copaxone®	Kesimpta®	Plegridy®	Rebif®	Lemtrada®	Ocrevus®	Tysabri®	Botox®	Fampyra®	Sativex®
Generic name	teriflunomide	fingolimod	cladribine tablets	siponimod	dimethyl fumarate	ozanimod	interferon b-1a	interferon b-1b	glatiramer acetate	ofatumumab	interferon b-1a (pegylated)	interferon b-1a	alemtuzumab	ocrelizumab	natalizumab	botulinum toxin type A	fampridine	nabiximols
Manufacturer	Sanofi Genzyme	Novartis Australia	Merck	Novartis Australia	Biogen	Bristol Myers Squibb	Biogen	Bayer Australia	Teva	Novartis	Biogen	Merck Serono	Sanofi Genzyme	Roche	Biogen	Allergan	Biogen	Emerge Health Pty Ltd
Indications (forms of MS that the treatment is used for)	Relapsing remitting MS (RRMS)	Relapsing forms of MS (RRMS and relapsing SPMS)	RRMS	SPMS	RRMS	RRMS	RRMS	Single clinical event indicating high risk of MS, RRMS, SPMS	Single clinical event indicating high risk of MS & RRMS	RRMS	RRMS	Single clinical event indicating high risk of MS & RRMS	RRMS	RRMS & Primary Progressive MS (PPMS)	RRMS (Use in paediatric patients with RRMS approved by Gov't 28/10/19 effective 1/11/19)	Any form of MS; for treatment of urinary incontinence	Any form of MS; to improve walking	Muscle stiffness (spasticity)
Route	oral tablet	oral capsule	oral tablet	oral tablet	oral capsule	oral capsule	intramuscular injection	subcutaneous injection	subcutaneous injection	subcutaneous injection	subcutaneous injection	subcutaneous injection	intravenous infusion	intravenous infusion	intravenous infusion	intramuscular injection	oral tablet	oromucosal (mouth) spray
Dosage and Frequency	one 14 mg tablet per day	Adults and paediatric patients over 40 kg: one 0.5 mg capsule per day Paediatric patients 40kg and under: 0.25mg capsule per day	Two treatment courses over two years; each treatment course consists of two weeks.	once daily	one 120mg capsule twice daily, increasing to 240g twice daily	once daily after initial titration	once per week	every two days	40 mg, three times per week OR 20 mg daily (20 mg dose not available after 1-7-19)	Inject 20mg under the skin on week 0, week 1 and week 2. There is no injection at week 3. At week 4 and then every month, inject 20mg under the skin	every two weeks	three times per week	two treatment courses, 1 year apart	6 monthly; first treatment is split into 2 doses a fortnight apart	every 28 days	single treatment	Two tablets per day, 12 hours apart	A number of sprays per day depending on individual circumstances
Preparation	film coated oral tablet	gel capsules	uncoated tablets	film coated oral tablet	capsule	capsule	pre-filled syringe	pre-filled syringe	pre-filled syringe	pre-filled syringe	single-use, pre-filled injection pens	pre-filled cartridge	prepared by pharmacy or clinic staff	prepared by pharmacy or clinic staff	prepared by pharmacy or clinic staff	multiple injections by doctor during one visit	film coated oral tablet	10mL glass spray container and a pump
Storage	room temperature, below 30°C	room temperature, below 30°C	room temperature, below 25°C	refrigerate 2-8°C	room temperature, below 30°C	room temperature between 20-25°C	refrigerate 2-8°C	room temperature, below 25°C	refrigerate 2-8°C	refrigerate 2-8°C	refrigerate 2-8°C	refrigerate 2-8°C	stored in the pharmacy or clinic at 2-8°C	stored in the pharmacy or clinic at 2-8°C	stored in the pharmacy or clinic at 2-8°C	doctor will arrange storage	room temperature, below 25°C	refrigerate 2-8°C
Available on PBS	Yes	0.5mg dosage capsules - yes 0.25mg capsules - yes from 1 Nov 2019	Yes (from 1 Jan 2019)	Yes (from 1 Nov 2020)	Yes	Yes (from 1 March 2021)	Yes	Yes, RRMS only, not for single clinical event	Yes, RRMS only, not for single clinical event. 20 mg dose deleted from PBS from 1-7-19	Submitted to March 2021 PBAC meeting for PBS listing, awaiting outcome	Yes	Yes, RRMS only, not for single clinical event	Yes	RRMS Yes PPMS No	Yes (from 1/11/19 for paediatric patients)	Yes	No	No

Note 1: A generic version of teriflunomide is now available, please visit: <https://www.msaustralia.org.au/about-ms/medications-treatments>